Genmab (CPH:GEN)

QUOTE AND NEWS
SeekingAlpha  Aug 13  Comment 
Genmab A/S (OTC:GNMSF) Q2 2014 Earnings Conference Call August 13, 2014 12:00 PM ET Executives Jan G. J. van de Winkel – President and Chief Executive Officer David A. Eatwell – Executive Vice President & Chief Financial...
StreetInsider.com  Jul 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GlaxoSmithKline+plc+%28GSK%29%2C+Genmab+Report+PROLONG+Phase+III+Met+Primary+Endpoint/9709147.html for the full story.
newratings.com  Jul 3  Comment 
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Denmark-based biotechnology company Genmab A/S (GMXAY.PK, GNMSF.PK) announced that the European Commission or EC has granted marketing authorization for a new indication for the use of...
FierceBiotech  Jul 2  Comment 
Welcome to the latest edition of our weekly EuroBiotech Report. With the battle for investor support in the AbbVie-Shire takeover tug of war heating up, the Ireland-headquartered biopharma has played up its European roots and rare position in the...
StreetInsider.com  Jun 27  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Glaxo+%28GSK%29%2C+Genmab+Report+Arzerra+Phase+III+Missed+Primary+Endpoint/9620262.html for the full story.
StreetInsider.com  May 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Glaxo+%28GSK%29%2C+Genmab+Report+Ofatumumab+Phase+III+Missed+Primary+Endpoint/9502227.html for the full story.
StreetInsider.com  May 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GlaxoSmithKline+%28GSK%29+and+Genmab+AS+Ph-3+Study+of+Arzerra+Doesn%27t+Meet+Endpoint/9502178.html for the full story.
StreetInsider.com  Apr 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GSK+%28GSK%29+and+Genmab+Receive+FDA+Approval+for+Wider+Use+of+Arzerra/9390464.html for the full story.
newratings.com  Apr 17  Comment 
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Genmab A/S said Thursday that the U.S. Food and Drug Administration has approved a Supplemental Biologic License Application for the use of Arzerra, a CD20-directed monoclonal antibody, in...
FierceBiotech  Mar 27  Comment 
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki